Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 767-775

  Diaz Padilla, Ivan ^a,b   Duran, Ignacio ^b   Clarke, Blaise A ^a   Oza, Amit M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HM Hospitales Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

Author keywords

Cervical cancer; Endometrial cancer; Everolimus; MTOR; Ovarian cancer; Ridaforolimus; Temsirolimus

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RIDAFOROLIMUS; TEMSIROLIMUS;

ANEMIA; ANOREXIA; CANCER CHEMOTHERAPY; CELL CYCLE PROGRESSION; CELL GROWTH; CELL METABOLISM; DIARRHEA; DRUG ACTIVITY; DRUG RESEARCH; ENDOMETRIUM CANCER; FATIGUE; GYNECOLOGIC CANCER; HUMAN; HYPERGLYCEMIA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; RASH; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84861690519     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.001     Document Type: Review

References (104)

1. Ozols R.F. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006, 33:S3-11.
2. Burger R.A., Brady M.F., Bookman M.A., et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010, 28:18s. [Suppl; abstr LBA1].
3. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
4. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
5. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
6. Shayesteh L., Lu Y., Kuo W.L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21:99-102.
7. Broderick D.K., Di C., Parrett T.J., et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004, 64:5048-5050.
8. Saal L.H., Holm K., Maurer M., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559.
9. Kong D., Suzuki A., Zou T.T., et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997, 17:143-144.
10. Minaguchi T., Yoshikawa H., Oda K., et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001, 7:2636-2642.
11. Oda K., Stokoe D., Taketani Y., et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-10673.
12. Altomare D.A., Wang H.Q., Skele K.L., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.
13. Contreras-Paredes A., De la Cruz-Hernandez E., Martinez-Ramirez I., et al. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 2009, 383:78-85.
14. Feng W., Duan X., Liu J., et al. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2009, 2:249-260.
15. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
16. Hess G., Smith S.M., Berkenblit A., et al. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol 2009, 36(Suppl 3):S37-45.
17. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000, 356:194-202.
18. Cohen E.E., Sharma M.R., Janisch L., et al. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer 2011, 47:1484-1489.
19. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006, 12:860-868.
20. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
21. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
22. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
23. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
24. Chawla S.P., Blay J., Ray-Coquard I.L., et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011, 29. [Suppl; abstr 10005].
25. Yuan R., Kay A., Berg W.J., et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2:45.
26. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
27. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
28. O'Reilly K.E., Rojo F., She Q.B., et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
29. Wan X., Harkavy B., Shen N., et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
30. Carracedo A., Ma L., Teruya-Feldstein J., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
31. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118:3051-3064.
32. Wee S., Jagani Z., Xiang K.X., et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
33. Ihle N.T., Lemos R., Wipf P., et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009, 69:143-150.
34. Lane H.A., Breuleux M. Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 2009, 21:219-229.
35. Shen W.H., Balajee A.S., Wang J., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
36. Puc J., Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 2005, 4:927-929.
37. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
38. Dedes K.J., Wetterskog D., Mendes-Pereira A.M., et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2:53ra75.
39. Forster M.D., Dedes K.J., Sandhu S., et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011, 8:302-306.
40. Llobet D., Pallares J., Yeramian A., et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009, 62:777-785.
41. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98:10314-10319.
42. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 2001, 98:10320-10325.
43. Hayes M.P., Douglas W., Ellenson L.H. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009, 113:370-373.
44. Urick M.E., Rudd M.L., Godwin A.K., et al. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011, 71:4061-4067.
45. Mountzios G., Pectasides D., Bournakis E., et al. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol 2010, 79:278-292.
46. Oza A.M., Elit L., Tsao M.S., et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the ncic clinical trials group. J Clin Oncol 2011, 29:3278-3285.
47. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116:5415-9.
48. Colombo N., McMeekin S., Schwartz P., et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. ASCO Meet Abstr 2007, 25:5516.
49. Mackay H., Welch S., Tsao M.S., et al. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. J Clin Oncol 2011, 29. [Suppl; abstr 5013].
50. Kokka F., Brockbank E., Oram D., et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010, CD007926.
51. Beeram M., Tan Q.T., Tekmal R.R., et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18:1323-1328.
52. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011, [Epub ahead of print].
53. Fleming G.F., Filiaci V.L., Hanjani P., et al. Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. J Clin Oncol 2011, 29. [Suppl; abstr 5014].
54. Slomovitz B.M., Brown J., Johnston T.A., et al. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2011, 29. [Suppl; abstr 5012].
55. Oza A.M., Poveda A., Clamp A.R., et al. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. J Clin Oncol 2011, 29. [Suppl; abstr 5009].
56. Kurman R.J., Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443.
57. Kuo K.T., Guan B., Feng Y., et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009, 69:4036-4042.
58. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
59. Campbell I.G., Russell S.E., Choong D.Y., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681.
60. Yuan Z.Q., Sun M., Feldman R.I., et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000, 19:2324-2330.
61. Page C., Lin H.J., Jin Y., et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000, 20:407-416.
62. Hu L., Hofmann J., Lu Y., et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002, 62:1087-1092.
63. Guarneri V., Barbieri E., Dieci M.V., et al. Timing for starting second-line therapy in recurrent ovarian cancer. Expert Rev Anticancer Ther 2011, 11:49-55.
64. Behbakht K., Sill M.W., Darcy K.M., et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011.
65. Mabuchi S., Altomare D.A., Connolly D.C., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007, 67:2408-2413.
66. Manenti L., Riccardi E., Marchini S., et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 2005, 4:715-725.
67. Morgan R., Oza A.M., Qin R., et al. A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: ovarian cancer (OC) subset - a study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol 2011, 29. [Suppl; abstr 5015].
68. Bosch F.X., Lorincz A., Munoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
69. Smith H.O., Tiffany M.F., Qualls C.R., et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000, 78:97-105.
70. Contag S.A., Gostout B.S., Clayton A.C., et al. Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol 2004, 95:610-617.
71. Lea J.S., Sheets E.E., Wenham R.M., et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002, 84:115-119.
72. Zhang X.Y., Zhang H.Y., Zhang P.N., et al. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008, 139:237-244.
73. Heselmeyer K., Schrock E., du Manoir S., et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 1996, 93:479-484.
74. Bertelsen B.I., Steine S.J., Sandvei R., et al. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006, 118:1877-1883.
75. Lu Z., Hu X., Li Y., et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004, 279:35664-35670.
76. Oh K.J., Kalinina A., Park N.H., et al. Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein. J Virol 2006, 80:7079-7088.
77. Hall A.H., Alexander K.A. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003, 77:6066-6069.
78. Ji J., Zheng P.S. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 2010, 117:103-108.
79. Tinker A., Mackay H., Ellard S., Welch S., Eisenhauer E. Preliminary activity of Temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: a NCIC-CTG phase II clinical trial. Mol Cancer Ther 2011, 10(11 Suppl):C69.
80. Bae-Jump V.L., Zhou C., Boggess J.F., et al. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009, 115:3887-3896.
81. Shafer A, Zhou C, Gehrig PA, et al. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 126:1144-54.
82. Kollmannsberger C., Hirte H., Siu L.L., et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 2011, [Epub ahead of print].
83. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
84. Campone M., Levy V., Bourbouloux E., et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009, 100:315-321.
85. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 117:473-6.
86. Bellmunt J., Szczylik C., Feingold J., et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008, 19:1387-1392.
87. Rodriguez-Pascual J., Cheng E., Maroto P., et al. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 2010, 21:478-486.
88. Friberg E., Orsini N., Mantzoros C.S., et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007, 50:1365-1374.
89. Friedenreich C.M., Biel R.K., Lau D.C., et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:2384-2395.
90. Duran I., Siu L.L., Oza A.M., et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42:1875-1880.
91. Maroto J.P., Hudes G., Dutcher J.P., et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011, 29:1750-1756.
92. Monk B.J., Sill M.W., Burger R.A., et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2009, 27:1069-1074.
93. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009, 102:19-65.
94. Kikuchi Y., Kudoh K., Takano M., et al. Effects of treatment by temsirolimus on patients with clear cell carcinoma of the ovary. J Clin Oncol 2010, 28:15s. [Suppl; abstr 5086].
95. Mwandoro T.N., Gao F., Lockhart A.C., et al. Phase I study of docetaxel and temsirolimus in refractory solid tumors. J Clin Oncol 2010, 28. [Suppl; abstr e13149].
96. Moroney J.W., Coleman R.L., Hong D.S., et al. A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. J Clin Oncol 2009, 27. [Suppl; abstr e13508].
97. Di Cosimo S., Bendell J.C., Cervantes-Ruiperez A., et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28:15s. [Suppl; abstr 3008].
98. Beauchamp M.C., Yasmeen A., Knafo A., et al. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010, 2010:257058.
99. Kurzrock R., Patnaik A., Rosenstein L., et al. Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol 2011, 29. [Suppl; abstr 3085].
100. Shimizu T., Tolcher A.W., Papadopoulos K.P., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012, [Epub ahead of print].
101. Vilar E., Perez-Garcia J., Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011, 10:395-403.
102. Albert S., Serova M., Dreyer C., et al. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010, 19:919-930.
103. Santiskulvong C., Konecny G.E., Fekete M., et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011, 17:2373-2384.
104. Delbaldo C., Albert S., Dreyer C., et al. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target Oncol 2011, 6:119-124.